Drug Trial Radar · NCT04303169
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Jun 26, 2020
Primary completion
Sep 24, 2025
Study completion Sep 24, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02C is to evaluate the safety and efficacy of investigational treatment arms in participants with Stage III melanoma who are candidates for neoadjuvant therapy to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. Arm 1: Pembrolizumab + Vibostolimab, Arm 2: Pembrolizumab + Gebasaxturev, and Arm 3: Pembrolizumab were added in the base protocol on 13-Nov-2019, and enrollment into those arms has been completed. Arm 4: Pembrolizumab + MK-4830 was added in Amendment 04 on 20-Dec-2021, and enrollment into that arm has been completed. Arm 5: Favezelimab + Pembrolizumab and Arm 6: Pembrolizumab + all-trans retinoic acid (ATRA) were added in Amendment 06 on 25-Jun-2022, and enrollment is ongoing.
Conditions
- Melanoma
Interventions
PembrolizumabBiological
Administered via IV infusion at a specified dose on specified days
VibostolimabBiological
Administered via IV infusion at a specified dose on specified days
GebasaxturevBiological
Administered via IT injection at a specified dose on specified days
MK-4830Biological
Administered via IV infusion at a specified dose on specified days
Favezelimab + PembrolizumabBiological
Administered via IV infusion at a specified dose on specified days
ATRADrug
Administered via oral capsules at a specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 17 months
- Percentage of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 13 months
- Pathological Complete Response (pCR) Rate With 90% Confidence Interval (CI)Time frame: Up to approximately 6 weeks
- pCR Rate With 95% CITime frame: Up to approximately 6 weeks
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute ( Site 3009)
Los Angeles, California
Providence Saint John's Health Center ( Site 3010)
Santa Monica, California
University of Colorado, Anschutz Cancer Pavilion ( Site 3012)
Aurora, Colorado
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 3022)
Baltimore, Maryland
NYU Clinical Cancer Center ( Site 3002)
New York, New York
Duke Cancer Institute ( Site 3005)
Durham, North Carolina
Martha Morehouse Tower ( Site 3020)
Columbus, Ohio
Oregon Health & Science University ( Site 3013)
Portland, Oregon
University of Pennsylvania Abramson Cancer Center ( Site 3008)
Philadelphia, Pennsylvania
West Cancer Center - East Campus ( Site 3014)
Germantown, Tennessee
Inova Schar Cancer Institute ( Site 3011)
Fairfax, Virginia
Melanoma Institute Australia ( Site 3402)
Wollstonecraft, New South Wales, Australia
Tasman Oncology Research Pty Ltd ( Site 3403)
Southport, Queensland, Australia
Fiona Stanley Hospital ( Site 3401)
Murdoch, Western Australia, Australia
A.P.H. Paris, Hopital Saint Louis ( Site 3107)
Paris, France
Hopital La Timone ( Site 3103)
Marseille, Bouches-du-Rhone, France
Institut Claudius Regaud ( Site 3105)
Toulouse, Haute-Garonne, France
Gustave Roussy ( Site 3101)
Villejuif, Île-de-France Region, France
Centre Hospitalier Lyon Sud ( Site 3102)
Pierre-Bénite, Rhone, France
HaEmek Medical Center ( Site 3703)
Afula, Israel
Rambam Health Care Campus-Oncology ( Site 3704)
Haifa, Israel
Hadassah Ein Karem Jerusalem ( Site 3702)
Jerusalem, Israel
Rabin Medical Center-Oncology ( Site 3705)
Petah Tikva, Israel
Chaim Sheba Medical Center ( Site 3701)
Ramat Gan, Israel
Istituto Europeo di Oncologia ( Site 3301)
Milan, Italy
Policlinico Le Scotte - A.O. Senese ( Site 3377)
Siena, Italy
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 3603)
Geneva, Canton of Geneva, Switzerland
CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602)
Lausanne, Canton of Vaud, Switzerland
Universitaetsspital Zuerich ( Site 3601)
Zuerich Flughafen, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.